HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Centre on Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada.
Harm Reduct J. 2024 Aug 14;21(1):147. doi: 10.1186/s12954-024-01072-0.
Prisons often serve as high-risk environments for drug use, and incarcerated people are at a high risk for substance use-related mental and physical harms. This study aimed to determine the prevalence of non-injection drug use inside the prison and its related factors among incarcerated people in Iran.
We utilized data from three national bio-behavioral surveillance surveys conducted among incarcerated people in Iran in 2009, 2013, and 2017. Eligibility criteria were being ≥ 18 years old, providing informed consent, and being incarcerated for over a week. Overall, 17,228 participants across all surveys were recruited through a multi-stage random sampling approach. Each participant underwent a face-to-face interview and HIV test. The primary objective of the study was to assess self-reported non-injection drug use within the prison environment within the last month. A multivariable logistic regression model was built to determine associated covariates with drug use inside prison and an adjusted odds ratio (aOR) with 95% confidence intervals (CI) were reported.
The prevalence of non-injection drug use inside the prison was 24.1% (95% CI 23.5, 24.7) with a significant decreasing trend (39.7% in 2009, 17.8% in 2013, 14.0% in 2017; p-value < 0.001). Overall, 44.0% of those who used drugs were also receiving opioid agonist therapy (OAT) and we noted that in 2017, 75.1% of those on OAT used stimulants. In the multivariable logistic regression model, the year of interview (2013: aOR = 1.43 and 2009: aOR = 5.60), younger age (19-29: aOR = 1.14 and 30-40: aOR = 1.37), male sex (aOR = 3.35), < high school education (aOR = 1.31), having a history of previous incarceration (aOR = 1.26), and having a history of lifetime HIV testing (aOR = 1.76) were significantly and positively associated with recent non-injection drug use inside the prison.
Approximately one in four incarcerated people in Iran reported drug use within the last month inside prisons. While a declining trend in non-injection drug use was noted, substantial gaps persist in harm reduction programs within Iranian prisons. In particular, there is a pressing need for improvements in drug treatment programs, focusing on the integration of initiatives specifically designed for people who use stimulants.
监狱通常是药物滥用的高风险环境,被监禁者存在与物质使用相关的身心伤害的高风险。本研究旨在确定伊朗被监禁者在监狱内使用非注射类药物的流行情况及其相关因素。
我们利用了 2009 年、2013 年和 2017 年在伊朗进行的三次全国生物行为监测调查的数据。入选标准为年龄≥18 岁、提供知情同意书以及被监禁超过一周。在所有调查中,共有 17228 名符合条件的参与者通过多阶段随机抽样方法入选。每位参与者都接受了面对面的访谈和 HIV 检测。本研究的主要目的是评估在过去一个月内自我报告的在监狱环境中使用非注射类药物的情况。建立了多变量逻辑回归模型来确定与监狱内药物使用相关的协变量,并报告了调整后的比值比(aOR)及其 95%置信区间(CI)。
监狱内非注射类药物使用的流行率为 24.1%(95%CI 23.5,24.7),呈显著下降趋势(2009 年为 39.7%,2013 年为 17.8%,2017 年为 14.0%;p 值<0.001)。总体而言,44.0%的药物使用者也接受了阿片类激动剂治疗(OAT),我们注意到,2017 年,75.1%的 OAT 使用者使用了兴奋剂。在多变量逻辑回归模型中,访谈年份(2013 年:aOR=1.43 和 2009 年:aOR=5.60)、年龄较轻(19-29 岁:aOR=1.14 和 30-40 岁:aOR=1.37)、男性(aOR=3.35)、未接受过高中教育(aOR=1.31)、有既往监禁史(aOR=1.26)和有既往终身 HIV 检测史(aOR=1.76)与最近在监狱内使用非注射类药物显著正相关。
伊朗约有四分之一的被监禁者报告在过去一个月内在监狱内使用过药物。虽然非注射类药物使用呈下降趋势,但伊朗监狱内的减少伤害方案仍存在显著差距。特别是,需要改善药物治疗方案,重点是为使用兴奋剂的人专门设计的举措的整合。